January 18, 2018 11:37 AM EST

The next Emflaza: Acer Therapeutics looks to take a page out of Marathon's book

Zachary Brennan

Senior Editor

Last year, Marathon Pharmaceuticals took an inexpensive steroid available for sale in the EU and Canada and brought it through the US FDA approval process …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

TRENDING NOW

The next Emflaza: Acer Therapeutics looks to take a page out of Marathon's book

Zachary Brennan

Senior Editor

Sign up to read this article for free.

The ‘MAHA report’: Four key takeaways on vaccines, medicine and the pharma industry

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

FDA chief to senators: 3,000+ staff departures won't delay user fee targets

House passes Trump tax bill with PBM and orphan drug reforms included

Sanofi makes $470M move for Vigil's Alzheimer's drug, while another asset returns to Amgen

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

The next Em­flaza: Ac­er Ther­a­peu­tics looks to take a page out of Marathon's book

Zachary Brennan

Senior Editor

Sign up to read this article for free.

The ‘MA­HA re­port’: Four key take­aways on vac­cines, med­i­cine and the phar­ma in­dus­try

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

FDA chief to sen­a­tors: 3,000+ staff de­par­tures won't de­lay user fee tar­gets

House pass­es Trump tax bill with PBM and or­phan drug re­forms in­clud­ed

Sanofi makes $470M move for Vig­il's Alzheimer's drug, while an­oth­er as­set re­turns to Am­gen

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

The next Emflaza: Acer Therapeutics looks to take a page out of Marathon's book

The ‘MAHA report’: Four key takeaways on vaccines, medicine and the pharma industry

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

FDA chief to senators: 3,000+ staff departures won't delay user fee targets

House passes Trump tax bill with PBM and orphan drug reforms included

Sanofi makes $470M move for Vigil's Alzheimer's drug, while another asset returns to Amgen

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?